- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Eric Donnenfeld Talks Xdemvy Approval, Effect on Patients
Eric Donnenfeld, MD, from Ophthalmic Consultants of Long Island, discusses the importance of the Xdemvy FDA approval in treating patients with Demodex blepharitis.
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, discussed how treatment for Demodex blepharitis and Demodex mites will change with the recent approval of Xdemvy.
Transcript
How will the approval of Xdemvy change the way that Demodex mites and Demodex blepharitis are treated?
So it's very exciting that Xdemvy, the generic name is lotilaner, was approved by the FDA in late July. This is the first FDA-approved medication for treating Demodex blepharitis.
Demodex blepharitis is one of the most common diseases that we face on an everyday basis in our clinics and is responsible for ocular redness, irritation, many times with itching, and can participate in development of meibomian gland dysfunction. So, for the first time, we have a drug that can treat 1 of the most common diseases we see on a regular basis that impacts the ocular surface, and I feel that Xdemvy will have a profound effect on improving patient's ocular surface as well as improving their eyes and making them appear less red.
How are patients responding now that this treatment is available?
Xdemvy was recently approved, and it's been really a home run with a lot of interest in using Xdemvy for treating Demodex blepharitis. And this just makes sense, because we don't really have treatments that are available for this common disease. Early data shows that patients are responding to this treatment with Xdemvy, and I, personally, have had several patients who've had chronic, recrudescent inflammation, redness, and uncomfortableness in their lids who have responded beautifully to the use of this new medication.
So, it's wonderful that for the first time we have a drug that can actually treat one of the most common diseases we see in our clinic on a daily basis.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC
June 23rd 2025The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
June 20th 2025Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.
Read More
